Next Article in Journal
Fermentation Strategies for Production of Pharmaceutical Terpenoids in Engineered Yeast
Next Article in Special Issue
Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits
Previous Article in Journal
The Neural Network of Neuropeptide S (NPS): Implications in Food Intake and Gastrointestinal Functions
Previous Article in Special Issue
A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies
Article

Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model

1
The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
2
Microbiotix, Inc., Worcester, MA 01605, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Ioannis Tsinopoulos, Ioanna Mylona and Lampros Lamprogiannis
Pharmaceuticals 2021, 14(4), 294; https://doi.org/10.3390/ph14040294
Received: 4 March 2021 / Revised: 19 March 2021 / Accepted: 24 March 2021 / Published: 26 March 2021
(This article belongs to the Special Issue Advances in Ocular Pharmacology)
Presently, there is no FDA- or EMA-approved antiviral for the treatment of human adenovirus (HAdV) ocular infections. This study determined the antiviral activity of filociclovir (FCV) against ocular HAdV isolates in vitro and in the Ad5/NZW rabbit ocular model. The 50% effective concentrations (EC50) of FCV and cidofovir (CDV) were determined for several ocular HAdV types using standard plaque reduction assays. Rabbits were topically inoculated in both eyes with HAdV5. On day 1, the rabbits were divided into four topical treatment groups: (1) 0.5% FCV 4x/day × 10 d; (2) 0.1% FCV 4x/day × 10 d; (3) 0.5% CDV 2x/day × 7 d; (4) vehicle 4x/day × 10 d. Eyes were cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14. The resulting viral eye titers were determined using standard plaque assays. The mean in vitro EC50 for FCV against tested HAdV types ranged from 0.50 to 4.68 µM, whereas those treated with CDV ranged from 0.49 to 30.3 µM. In vivo, compared to vehicle, 0.5% FCV, 0.1% FCV, and 0.5% CDV produced lower eye titers, fewer numbers of positive eye cultures, and shorter durations of eye infection. FCV demonstrated anti-adenovirus activity in vitro and in vivo. View Full-Text
Keywords: filociclovir; antiviral; eye; adenovirus; EKC; in vitro; animal model filociclovir; antiviral; eye; adenovirus; EKC; in vitro; animal model
Show Figures

Figure 1

MDPI and ACS Style

Romanowski, E.G.; Hussein, I.T.M.; Cardinale, S.C.; Butler, M.M.; Morin, L.R.; Bowlin, T.L.; Yates, K.A.; Shanks, R.M.Q.; Kowalski, R.P. Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model. Pharmaceuticals 2021, 14, 294. https://doi.org/10.3390/ph14040294

AMA Style

Romanowski EG, Hussein ITM, Cardinale SC, Butler MM, Morin LR, Bowlin TL, Yates KA, Shanks RMQ, Kowalski RP. Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model. Pharmaceuticals. 2021; 14(4):294. https://doi.org/10.3390/ph14040294

Chicago/Turabian Style

Romanowski, Eric G., Islam T.M. Hussein, Steven C. Cardinale, Michelle M. Butler, Lucas R. Morin, Terry L. Bowlin, Kathleen A. Yates, Robert M.Q. Shanks, and Regis P. Kowalski 2021. "Filociclovir Is an Active Antiviral Agent against Ocular Adenovirus Isolates In Vitro and in the Ad5/NZW Rabbit Ocular Model" Pharmaceuticals 14, no. 4: 294. https://doi.org/10.3390/ph14040294

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop